Mankind Pharma Limited (NSE:MANKIND)
India · Delayed Price · Currency is INR | Market Cap | 980.71B -1.3% |
| Revenue (ttm) | 142.78B +17.0% |
| Net Income | 19.13B -3.9% |
| EPS | 46.28 -5.9% |
| Shares Out | 412.83M |
| PE Ratio | 51.33 |
| Forward PE | 41.36 |
| Dividend | 2.00 (0.08%) |
| Ex-Dividend Date | n/a |
| Volume | 2,347,734 |
| Open | 2,429.80 |
| Previous Close | 2,420.40 |
| Day's Range | 2,363.20 - 2,468.80 |
| 52-Week Range | 1,909.70 - 2,716.50 |
| Beta | 0.47 |
| Analysts | Buy |
| Price Target | 2,653.40 (+11.69%) |
| Earnings Date | May 19, 2026 |
About Mankind Pharma
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin a... [Read more]
Financial Performance
In fiscal year 2026, Mankind Pharma's revenue was 142.78 billion, an increase of 16.96% compared to the previous year's 122.07 billion. Earnings were 19.13 billion, a decrease of -3.92%.
Financial StatementsNews
Mankind Pharma Transcript: Q4 25/26
Q4 and FY26 saw strong revenue and margin growth, led by domestic and specialty businesses, with chronic therapies outperforming and OTC channels expanding. FY27 guidance targets double-digit revenue growth, higher CapEx for biotech, and improved margins, despite raw material cost risks.
Mankind Pharma Quarterly report: Q4 2026
Mankind Pharma has published its Q4 2026 quarterly earnings report on May 20, 2026.
Mankind Pharma Slides: Q4 2026
Mankind Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 20, 2026.
Mankind Pharma Transcript: Q3 25/26
Revenue and profit grew year-over-year, driven by strong chronic therapy and export performance, while acute and OTC segments are recovering post-restructuring. Working capital and debt metrics improved, and management expects double-digit growth ahead.
Mankind Pharma Quarterly report: Q3 2026
Mankind Pharma has published its Q3 2026 quarterly earnings report on February 3, 2026.
Mankind Pharma Slides: Q3 2026
Mankind Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 3, 2026.
Mankind Pharma Transcript: Q2 25/26
Revenue grew 21% year-over-year in Q2 FY26, with EBITDA margin at 25%. BSV and exports drove strong growth, while GST disruptions and higher costs impacted margins. Guidance for full-year EBITDA margin and BSV growth is maintained, with recovery expected in H2.
Mankind Pharma Quarterly report: Q2 2026
Mankind Pharma has published its Q2 2026 quarterly earnings report on November 6, 2025.
Mankind Pharma Slides: Q2 2026
Mankind Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 6, 2025.
Mankind Pharma Transcript: Q1 25/26
Q1 FY26 saw 24.5% revenue growth and 23.8% EBITDA margin, with strong domestic and international performance, though net profit declined 17.4% due to higher finance and depreciation costs. Guidance for margins and growth remains unchanged, with BSV expected to accelerate in H2.
Mankind Pharma Quarterly report: Q1 2026
Mankind Pharma has published its Q1 2026 quarterly earnings report on August 1, 2025.
Mankind Pharma Slides: Q1 2026
Mankind Pharma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 1, 2025.